Annexon, Inc. (ANNX)
NASDAQ: ANNX · Real-Time Price · USD
5.99
+0.19 (3.28%)
Apr 7, 2026, 4:00 PM EDT - Market closed
Annexon Employees
Annexon had 96 employees as of December 31, 2025. The number of employees decreased by 4 or -4.00% compared to the previous year.
Employees
96
Change
-4
Growth
-4.00%
Revenue / Employee
n/a
Profits / Employee
-$2,172,365
Market Cap
961.24M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 96 | -4 | -4.00% |
| Sep 30, 2025 | 99 | 15 | 17.86% |
| Jun 30, 2025 | 103 | 32 | 45.07% |
| Mar 31, 2025 | 106 | 36 | 51.43% |
| Dec 31, 2024 | 100 | 29 | 40.85% |
| Sep 30, 2024 | 84 | 8 | 10.53% |
| Jun 30, 2024 | 71 | -6 | -7.79% |
| Mar 31, 2024 | 70 | -10 | -12.50% |
| Dec 31, 2023 | 71 | -9 | -11.25% |
| Sep 30, 2023 | 76 | -7 | -8.43% |
| Jun 30, 2023 | 77 | 2 | 2.67% |
| Mar 31, 2023 | 80 | 17 | 26.98% |
| Dec 31, 2022 | 80 | 19 | 31.15% |
| Sep 30, 2022 | 83 | 21 | 33.87% |
| Jun 30, 2022 | 75 | 18 | 31.58% |
| Mar 31, 2022 | 63 | 15 | 31.25% |
| Dec 31, 2021 | 61 | 13 | 27.08% |
| Sep 30, 2021 | 62 | 24 | 63.16% |
| Jun 30, 2021 | 57 | 27 | 90.00% |
| Mar 31, 2021 | 48 | 18 | 60.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 562 |
| Xeris Biopharma Holdings | 435 |
| Phathom Pharmaceuticals | 371 |
| Vor Biopharma | 154 |
| Inhibrx Biosciences | 110 |
| Janux Therapeutics | 109 |
| Inventiva | 84 |
| GH Research | 73 |
ANNX News
- 8 days ago - Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewsWire
- 22 days ago - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 7 weeks ago - Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy - GlobeNewsWire
- 2 months ago - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 - GlobeNewsWire
- 3 months ago - Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome - GlobeNewsWire
- 3 months ago - Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire